190 results on '"Wilson, Timothy H."'
Search Results
2. Quantifying the Contribution of Symptom Improvement to Satisfaction of Men With Moderate to Severe Benign Prostatic Hyperplasia: 4-Year Data From the CombAT Trial
3. Nocturia improvement in the combination of Avodart® and tamsulosin (CombAT) study
4. Impact of dutasteride on nocturia in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): a pooled analysis of three phase III studies
5. Dutasteride Improves Outcomes of Benign Prostatic Hyperplasia When Evaluated for Prostate Cancer Risk Reduction: Secondary Analysis of the REduction by Dutasteride of Prostate Cancer Events (REDUCE) Trial
6. Dutasteride Reduces Prostatitis Symptoms Compared With Placebo in Men Enrolled in the REDUCE Study
7. Afterword "Saint-Porchaire": Some Signposts for Further Study
8. Effect of dutasteride on the risk of prostate cancer
9. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study
10. Predictors of Pathological Progression among Men with Localized Prostate Cancer Undergoing Active Surveillance: a Sub-Analysis of the REDEEM Study
11. The Effect of Dutasteride on the Peripheral and Transition Zones of the Prostate and the Value of the Transition Zone Index in Predicting Treatment Response
12. Comparison of the response to treatment between Asian and Caucasian men with benign prostatic hyperplasia: Long-term results from the combination of dutasteride and tamsulosin study
13. UTILITY OF PSA IN THE REDUCTION BY DUTASTERIDE OF CLINICAL PROGRESSION EVENTS IN EXPECTANT MANAGEMENT OF PROSTATE CANCER (REDEEM) STUDY: 2109
14. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS)
15. Low serum testosterone levels are poor predictors of sexual dysfunction
16. The effects of dutasteride or tamsulosin alone and in combination on storage and voiding symptoms in men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH): 4-year data from the Combination of Avodart and Tamsulosin (CombAT) study
17. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial
18. The Effect of Dutasteride on the Usefulness of Prostate Specific Antigen for the Diagnosis of High Grade and Clinically Relevant Prostate Cancer in Men With a Previous Negative Biopsy: Results From the REDUCE Study
19. Men’s Sexual Health Questionnaire score changes vs spontaneous sexual adverse event reporting in men treated with dutasteride/tamsulosin combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A post hoc analysis of a prospective, randomised, placebo‐controlled study
20. UTILITY OF COMBINING FINAL PSA AND PSA DYNAMICS (CHANGE FROM MONTH 6 TO FINAL PSA) FOR PROSTATE CANCER AND HIGH GRADE CANCER DIAGNOSIS IN THE REDUCTION BY DUTASTERIDE OF PROSTATE CANCER EVENTS (REDUCE) STUDY: 1981
21. EFFECT OF DUTASTERIDE ON THE DETECTION OF PROSTATE CANCER IN MEN WITH BENIGN PROSTATIC HYPERPLASIA IN THE COMBINATION OF AVODART AND TAMSULOSIN (COMBAT) STUDY: 1980
22. CLINICAL OUTCOMES BY BASELINE PROSTATE VOLUME IN MEN WITH BENIGN PROSTATIC HYPERPLASIA: 4 YEAR RESULTS FROM THE COMBINATION OF AVODART AND TAMSULOSIN (COMBAT) TRIAL: 1782
23. EFFICACY OF DUTASTERIDE ON BENIGN PROSTATIC HYPERPLASIA ENDPOINTS IN THE REDUCTION BY DUTASTERIDE OF PROSTATE CANCER EVENTS (REDUCE) STUDY ACCORDING TO BASELINE INTERNATIONAL PROSTATE SYMPTOM SCORE AND PROSTATE VOLUME: 1783
24. COMBINATION THERAPY WITH DUTASTERIDE AND TAMSULOSIN PROVIDED GREATER IMPROVEMENTS THAN EITHER MONOTHERAPY REGARDLESS OF PRIOR BENIGN PROSTATIC HYPERPLASIA OR LOWER URINARY TRACT TREATMENT STATUS: 1785
25. CAN PATIENTS WITH LUTS AND BPH DISCERN CHANGES IN PEAK URINARY FLOW RATE AND DO SUCH CHANGES CONTRIBUTE TO OVERALL SATISFACTION WITH TREATMENT?: 1798
26. IMPROVEMENTS IN STORAGE AND VOIDING SYMPTOMS WITH DUTASTERIDE, TAMSULOSIN AND THE COMBINATION: POST- HOC ANALYSIS OF THE 2-YEAR DATA FROM THE CombAT TRIAL: 2030
27. IS PSA INFLUENCED BY TESTOSTERONE LEVELS IN AGING MEN?: 869
28. Evaluation of the impact of dutasteride/tamsulosin combination therapy on libido in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH): A post hoc analysis of a prospective randomised placebo‐controlled study
29. Marked Suppression of Dihydrotestosterone in Men with Benign Prostatic Hyperplasia by Dutasteride, a Dual 5α-Reductase Inhibitor
30. Foucault, genealogy, history
31. MP40-12 ESTABLISHING A MINIMAL CLINICALLY MEANINGFUL DIFFERENCE IN THE MSHQ: NEW INSIGHTS
32. A prospective randomised placebo-controlled study of the impact of dutasteride/tamsulosin combination therapy on sexual function domains in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH)
33. Weekly glucagon-like peptide-1 receptor agonist albiglutide as monotherapy improves glycemic parameters in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study
34. Albiglutide efficacy and safety in the Latino/Hispanic subpopulation for the integrated phase III program
35. Albiglutide, a weekly GLP-1 receptor agonist, improves glycemic parameters in Japanese patients with type 2 diabetes over 1 year when added to single oral antidiabetic drugs
36. Evaluation of the impact of dutasteride/tamsulosin combination therapy on libido in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH): A post hoc analysis of a prospective randomised placebo-controlled study.
37. Weekly glucagon‐like peptide‐1 receptor agonist albiglutide as monotherapy improves glycemic parameters in Japanese patients with type 2 diabetes mellitus: A randomized, double‐blind, placebo‐controlled study.
38. A prospective randomised placebo‐controlled study of the impact of dutasteride/tamsulosin combination therapy on sexual function domains in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).
39. The question of representation in Elizabethan literature
40. Albiglutide, a weekly GLP-1 receptor agonist, improves glycemic parameters in Japanese patients with type 2 diabetes over 1 year when added to single oral antidiabetic drugs.
41. Modeling and Analysis of Gleason Score 8-10 Prostate Cancers in the REDUCE Study
42. The effect of dutasteride on the detection of prostate cancer: A set of meta-analyses
43. 1248 PHOSPHODIESTERASE TYPE 5 INHIBITOR USE IN THE COMBINATION OF AVODART® AND TAMSULOSIN (COMBAT) STUDY
44. 2109 UTILITY OF PSA IN THE REDUCTION BY DUTASTERIDE OF CLINICAL PROGRESSION EVENTS IN EXPECTANT MANAGEMENT OF PROSTATE CANCER (REDEEM) STUDY
45. 2136 EFFICACY OF DUTASTERIDE IN MEN WITH LOW PROSTATE VOLUME IN THE REDUCTION BY DUTASTERIDE OF PROSTATE CANCER EVENTS (REDUCE) STUDY
46. 1974 COMPARISON OF BENIGN PROSTATIC HYPERPLASIA OUTCOMES IN THE COMBINATION OF AVODART AND TAMSULOSIN (COMBAT) AND REDUCTION OF DUTASTERIDE IN CANCER EVENTS (REDUCE) STUDIES
47. Effect of Dutasteride on Prostate Biopsy Rates and the Diagnosis of Prostate Cancer in Men with Lower Urinary Tract Symptoms and Enlarged Prostates in the Combination of Avodart and Tamsulosin Trial
48. Low serum testosterone levels are poor predictors of sexual dysfunction
49. 797 DUTASTERIDE REDUCES PROSTATITIS SYMPTOMS COMPARED TO PLACEBO IN MEN ENROLLED IN THE REDUCE (REDUCTION BY DUTASTERIDE OF PROSTATE CANCER EVENTS) STUDY
50. 1981 UTILITY OF COMBINING FINAL PSA AND PSA DYNAMICS (CHANGE FROM MONTH 6 TO FINAL PSA) FOR PROSTATE CANCER AND HIGH GRADE CANCER DIAGNOSIS IN THE REDUCTION BY DUTASTERIDE OF PROSTATE CANCER EVENTS(REDUCE) STUDY
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.